This work was followed by a clinical trial by Nutt et al. in 2003 [67], who performed a double-blind multi-centric, placebo-controlled assessment of safety, tolerability, and biological activity of GDNF administered by an implanted intracerebroventricular (ICV) catheter in advanced PD. This evidence concerns the gene GDNF and Parkinson disease.